Nephrocare Health Services Limited, operating under the brand name NephroPlus, is Asia's largest dialysis network and ranks as the fifth-largest globally based on the number of treatments performed. The company has established a significant presence with over 520 clinics across more than 325 cities, serving a base of over 36,000 patients. While its core operations are in India, where it holds a dominant market share of over 50% in the organized sector, NephroPlus has successfully expanded its footprint internationally into high-growth markets including the Philippines, Uzbekistan, Nepal, and most recently, the Kingdom of Saudi Arabia. The company's mission is to redefine dialysis care and enable patients to lead normal lives, a philosophy deeply embedded in its operations and driven by the personal experience of its co-founder, Kamal Shah, who has been a dialysis patient for over two decades. This unique, patient-centric perspective informs their service delivery, which is designed to make patients feel like "guests" and is supported by initiatives like the "Dialysis Olympiad" and "Aashayein" guest forums. NephroPlus operates on a scalable, asset-light business model that includes partnerships with private hospitals (Captive clinics), public-private partnerships (PPPs) with government hospitals, and standalone centers. This adaptable model, combined with a strong focus on clinical excellence and operational efficiency, has enabled the company to bring quality dialysis care to underserved Tier II and Tier III cities, which constitute approximately 78% of its clinic network.

Official Website: www.nephroplus.com

• Strong Revenue Growth: For the third quarter of fiscal year 2026 (Q3 FY26), revenue from operations grew by 31.7% year-over-year (YoY) to ₹259.7 crores. For the nine months ending in FY26 (9M FY26), revenue increased by 36.6% YoY to ₹733.2 crores. This growth was driven by a 17.7% increase in treatment volumes in Q3 and a significant favorable mix shift towards international markets, which command higher revenue per treatment.

• Accelerating Profitability: Adjusted EBITDA for Q3 FY26 rose by 43.0% YoY to ₹63.1 crores, while for 9M FY26, it grew 52.1% to ₹175.4 crores. Adjusted Profit After Tax (PAT) demonstrated even stronger growth, increasing 71.3% in Q3 to ₹34.4 crores and 103.3% in 9M FY26 to ₹85.9 crores.

• Improving Operational Metrics: The number of patients served grew to 36,550 as of 9M FY26, a 15.5% YoY increase. The number of treatments performed in 9M FY26 reached 2.85 million, up 17.1% YoY. Revenue Per Treatment (RPT) saw a substantial uplift, growing 16.7% YoY in 9M FY26 to ₹2,574, reflecting the increasing contribution from higher-priced international operations.

• Enhanced Return on Capital: The annualized pre-tax Return on Capital Employed (ROCE) improved significantly, reaching 24.7% for 9M FY26, a 600 basis point expansion from 18.7% in the prior year. This highlights the company's ability to generate higher profits from its capital base.

• Consistent Historical Performance: The company has a strong track record, with revenue growing at a 31% Compound Annual Growth Rate (CAGR) between FY23 and FY25. During this period, the business model has demonstrated significant operating leverage.

The company is delivering robust, profitable growth, driven by a combination of increasing patient volumes and a strategic expansion into higher-value international markets, which is translating into superior returns on capital.

• Market Leadership and Unmatched Scale: NephroPlus is the largest dialysis network in India and Asia, with a scale that is 4.4 times that of its nearest organized competitor in India. This dominant position provides significant advantages in procurement, brand recognition, and partnerships.

• Asset-Light and Replicable Business Model: The company primarily operates through revenue-sharing models within private hospitals (Captive) and partnerships with government bodies (PPP), which account for approximately 52% of its clinics. This asset-light approach minimizes upfront capital investment, allows for rapid expansion, and generates quicker returns.

• India Cost Leadership Playbook: NephroPlus has developed a highly efficient operational framework in India that it is now replicating globally. This playbook is built on four pillars: lowest consumables cost per treatment through scale-led procurement and private labeling, an efficient human resource model with an in-house training academy, in-house biomedical maintenance to lower lifecycle costs, and strict overhead discipline.

• Proven M&A and Integration Capability: The company has a demonstrated track record of successfully acquiring and integrating other players, including the landmark acquisition of DaVita’s India operations. A dedicated business development team and a structured integration process allow acquired clinics to achieve operational breakeven in just 3-4 months, compared to 12 months for new greenfield clinics.

• Deeply Ingrained Patient-Centric Culture: The company's co-founder is a long-term dialysis patient, which fosters a unique, empathetic culture focused on patient well-being. This is a key qualitative differentiator that drives patient loyalty and service innovation.

• Focus on Clinical Excellence and Technology: NephroPlus maintains high clinical standards through its proprietary "RenAssure" protocols, its BONENT-accredited training academy "Enpidia," and technology like the patented "Renova" dialyzer reprocessing system. This focus on quality is validated by numerous JCI and NABH accreditations.

NephroPlus's distinct advantage lies in its combination of dominant market scale, a capital-efficient expansion model, a low-cost operational playbook, and a unique patient-first culture that drives clinical excellence.

• Strong Macro Tailwinds: The global dialysis market is driven by the rising incidence of Chronic Kidney Disease (CKD), which is fueled by the growing prevalence of non-communicable diseases like diabetes and hypertension. With 1 in 10 people globally suffering from CKD, the addressable market is large and expanding.

• Recurring and Non-Discretionary Service: Dialysis is a life-sustaining, recurring treatment required three times per week. This creates a highly predictable revenue stream with immense patient stickiness, as 95% of patients remain with the same clinic.

• Significant Underpenetration: A major gap exists between the number of patients requiring dialysis and those who have access to it, especially in emerging markets. The penetration rate in India is approximately 16%, in the Philippines it is ~35%, and in Uzbekistan it is ~27%, indicating substantial room for growth.

• High-Growth Markets: The dialysis services markets in NephroPlus's key geographies are projected to grow at rates significantly above the global average of ~7%. The Indian market is expected to grow at 19% CAGR (FY24-29E), the Philippines at 23%, and Uzbekistan at 17%.

• Shift to Organized Players: In India, there is a clear trend of market share shifting from the fragmented unorganized sector to organized chains like NephroPlus. The share of organized players is projected to increase from 16% in 2019 to 19% by 2029.

• Structurally Attractive Model: Compared to other single-specialty healthcare models like oncology or IVF, the dialysis model is asset-light, requires the lowest capital investment per center (₹10-15mn), and has the fastest payback period (1.5-2 years).

The company operates within a structurally attractive industry characterized by non-discretionary demand, significant under-penetration, and high growth, which is further supported by a clear shift towards organized providers.

• Aggressive International Expansion: International business is a primary growth engine, with its share of revenue increasing from 12% in FY23 to 41.1% in 9M FY26. This expansion into markets with higher price points (e.g., Philippines at 5.0x India prices, KSA at 13.6x) is a key driver of both revenue growth and margin enhancement.

• Strategic Inorganic Growth: Acquisitions are a core part of the growth strategy. The company has a proven ability to identify, acquire, and rapidly integrate smaller players or regional chains. In 9M FY26 alone, it completed 6 acquisitions totaling 9 clinics in the Philippines.

• Consolidating Leadership in India: NephroPlus continues to expand its domestic network by entering new micro-markets, pursuing large-scale PPP projects with state governments, and forming new partnerships with private hospitals.

• Sustained Volume Growth: The foundation of the company's growth is the consistent increase in its patient base and treatment volumes. The number of treatments grew at a CAGR of ~20.2% from FY23 to FY25, demonstrating strong execution and market demand.

Growth is powered by a multi-pronged strategy of aggressive international expansion into high-value markets, a disciplined M&A program, and continued consolidation of its leadership position in the domestic market.

• Entry into New High-Potential Markets: The company has a structured framework for evaluating and entering new international markets with favorable characteristics like high demand, established reimbursement policies, and regulatory stability. This provides a clear pathway for future geographic expansion.

• Tapping into Government Partnerships: Public-Private Partnerships (PPPs) represent a significant opportunity to expand access to dialysis in a capital-efficient manner, particularly in India. The company has a dedicated team focused on securing and managing these large-scale contracts.

• Gaining Share from the Unorganized Sector: The vast, fragmented unorganized market in India remains the largest source of potential market share gain. As patients increasingly prioritize quality and standardized care, NephroPlus is well-positioned to capture this shift.

• Leveraging Scale for Profitability: As the company continues to grow, its increasing scale creates opportunities for greater procurement efficiencies, leveraging centralized services, and exploring contract manufacturing for key consumables, which can further drive margin expansion.

The company has substantial opportunities for continued growth by entering new international markets, expanding government partnerships, and capturing market share from unorganized players, all while leveraging its scale to enhance profitability.

• Consolidate India Leadership Position: The company plans to deepen its presence in India by expanding into micro-markets and clusters with its asset-light model and focusing on PPP opportunities to become a preferred partner for public hospitals.

• Scale Operations in Key International Markets: The immediate focus is on scaling up operations in the Philippines, Uzbekistan, and the Kingdom of Saudi Arabia by strengthening the network, improving offerings, and growing the patient base.

• Further Expand into New Markets: NephroPlus will pursue a phased expansion into new international geographies that exhibit strong growth potential, low dialysis penetration, and opportunities to leverage its operational playbook.

• Leverage Scale to Drive Profitability: A key priority is to use its consolidated purchasing power to secure competitive pricing from manufacturers and scale up contract manufacturing of key consumables to improve cost efficiency and supply chain control.

• Drive Innovation-led Digital Healthcare: The company will continue to make strategic investments in technology, including its cloud-enabled Renova system, and leverage AI and predictive analytics to identify high-risk patients and optimize resource utilization.

The company's future strategy is clearly defined, focusing on deepening its domestic dominance while scaling existing and entering new international markets, all underpinned by leveraging technology and scale to drive profitability.

• Consistent Margin Expansion: NephroPlus has demonstrated a strong trend of improving profitability. The Adjusted EBITDA margin expanded from 11.1% in FY23 to 22.0% in FY25, and further to 23.9% in 9M FY26.

• Significant Improvement in Net Margin: The Adjusted PAT margin has shown remarkable improvement, turning from -2.7% in FY23 to 8.9% in FY25, and reaching 11.7% in 9M FY26. This reflects strong operating leverage, as profits are growing faster than revenues.

• Key Drivers of Margin Improvement: Margin expansion is primarily driven by three factors: 1) Increasing scale, which allows for better absorption of fixed costs; 2) A favorable business mix shift towards higher-margin international operations; and 3) Disciplined cost management through the "India Cost Leadership Playbook."

• Gross Margin Enhancement: The company's gross margin improved from 67.4% in FY23 to 74.3% in FY25, indicating strong control over the cost of consumables and direct service expenses.

The company has achieved consistent and significant margin expansion at all levels, driven by operating leverage, a strategic shift towards more profitable international markets, and disciplined cost control.

• Dominant Market Leader: In the organized Indian dialysis market, NephroPlus holds a commanding leadership position with a market share exceeding 50%. Its network is 4.4 times larger than that of the next closest organized competitor, giving it a significant competitive moat.

• Competition with Unorganized Sector: The primary competitive landscape in India consists of the large, fragmented unorganized sector, which includes single-center clinics and small, regional players. The company's growth is largely fueled by gaining share from this segment.

• Global Standing: On a global scale, NephroPlus is the fifth-largest dialysis network, which provides it with the scale to compete effectively in international markets and leverage global procurement relationships.

NephroPlus maintains a dominant leadership position in its core Indian market, being substantially larger than its organized peers, with its main competition coming from the fragmented unorganized sector.

• Recent Public Listing and Marquee Investors: The company recently listed on the Indian stock exchanges in December 2025. Its shareholder base includes prominent foreign institutional investors (FIIs) like Polar Capital and Fidelity, and domestic institutional investors (DIIs) such as SBI Mutual Fund and ICICI Prudential Mutual Fund.

• Entry into Saudi Arabia: NephroPlus has officially entered the Middle East market through a 51:49 joint venture with Tibbiyah. Its first clinic in Riyadh, equipped with 23 machines, is operationally ready and awaiting its final license.

• Continued M&A Activity: The company continues to actively pursue its inorganic growth strategy, having completed 6 acquisitions representing 9 clinics in the Philippines during the first nine months of FY26.

• Industry Recognition: The company has received several recent accolades, including a Guinness World Record in March 2025 for signing up the most people for an online kidney screening and an Innovation in Health award in February 2024, reinforcing its brand and industry leadership.

The company has recently achieved a successful public listing, attracting strong institutional backing, while continuing to execute its strategic goals with its operational launch in Saudi Arabia and ongoing acquisitions.